Latest News and Press Releases

Strasbourg (France), le 6 février 2025, 17 h 45 CET — Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des...

Strasbourg (France), February 6, 2025, 5:45 p.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, confirms...

Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The "Genomic Collaboration and Licensing Deals 2018-2024" report has been added to ResearchAndMarkets.com's offering. This report contains a...

Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "CGT Research Outlook and Technology Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. The report covers the...

Dublin, July 01, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapy R&D Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering. World revenue for Gene Therapy R&D Market is...

Dublin, June 21, 2024 (GLOBE NEWSWIRE) -- The "Adeno-associated Virus Gene Therapy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been...

Dublin, June 19, 2024 (GLOBE NEWSWIRE) -- The "Exosomes - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.An array of drugs is currently moving through various...

Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Genomic Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Genomic Collaboration and Licensing...

Les nouvelles données immunologiques de Phase I confirment la forte immunogénicité de TG4050 dans le traitement adjuvant des cancers de la tête et du cou.Tous les patients traités sont encore en...

Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of...